Beam Therapeutics (BEAM) Capital Expenditures (2019 - 2026)

Beam Therapeutics (BEAM) has reported Capital Expenditures for 8 consecutive years, with $2.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Capital Expenditures fell 27.18% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $438000.0 (down 70.02% YoY), while the FY2025 annual figure was $1.3 million, up 52.4% from the prior year.
• Capital Expenditures improved to $2.2 million in Q1 2026 per BEAM's latest filing, from -$1.9 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $31.8 million in Q3 2022 and bottomed at -$28.7 million in Q4 2023.
• Historically, Capital Expenditures has averaged $3.2 million across 5 years, with a median of $2.4 million in 2024.
• Annual changes were most pronounced in 2022 — Capital Expenditures surged 8173.51% — and 2025, when it plunged 584.33%.
• Beam Therapeutics' Capital Expenditures stood at $8.3 million in 2022, then slumped by 447.9% to -$28.7 million in 2023, then surged by 101.33% to $383000.0 in 2024, then slumped by 584.33% to -$1.9 million in 2025, then surged by 220.32% to $2.2 million in 2026.
• Business Quant data shows BEAM's Capital Expenditures at $2.2 million in Q1 2026, -$1.9 million in Q4 2025, and -$3.1 million in Q3 2025.